Get the Stockscreener App
61.30
1.13%
-0.70
After Hours:
60.90
-0.40
-0.65%
Mbx Biosciences Inc stock is traded at $61.30, with a volume of 303.84K.
It is down -1.13% in the last 24 hours and up +17.19% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
See More
Previous Close:
$62.00
Open:
$62.24
24h Volume:
303.84K
Relative Volume:
0.37
Market Cap:
$2.92B
Revenue:
-
Net Income/Loss:
$-86.97M
P/E Ratio:
-25.34
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
+1.93%
1M Performance:
+17.19%
6M Performance:
+69.95%
1Y Performance:
+320.73%
1-Day Range:
$60.40
$64.78
1-Week Range:
$57.23
$66.66
52-Week Range:
$9.63
$66.66
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
61.30 | 2.95B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences Inc (MBX) Institutional Confidence - TradingKey
MBX Biosciences, Inc. $MBX is Orbimed Advisors LLC's 10th Largest Position - MarketBeat
MBX Biosciences Inc (MBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MBX Biosciences Market Sentiment - Benzinga España
MBX Biosciences Inc (MBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MBX Biosciences Inc (MBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBX Biosciences, Inc. Revenue Breakdown – NASDAQ:MBX - TradingView
MBX Biosciences Inc (MBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MBX|MBX Biosciences Inc|Price:62.000|Chg%:-1.570 - TradingKey
TradingKey - TradingKey
MBX Biosciences Inc (MBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Affinity Asset Advisors LLC Reduces Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Sets New 12-Month HighHere's Why - MarketBeat
MBX Biosciences stock hits all-time high at 66.66 USD - Investing.com
MBX Biosciences stock hits all-time high at 66.66 USD By Investing.com - Investing.com Canada
MBX Biosciences (NASDAQ:MBX) Shares Up 6.5%Here's Why - MarketBeat
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MBX 8-K及美國證券交易委員會申報文件 - Yahoo 財經
MBX Biosciences (NASDAQ:MBX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
MBX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
MBX Biosciences (NASDAQ:MBX) Trading 5.1% HigherWhat's Next? - MarketBeat
Is MBX Biosciences (MBX) Fairly Valued As New Leadership Takes Charge? - Sahm
Attovia Therapeutics appoints John Smither to board By Investing.com - Investing.com Australia
Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating - Moomoo
Attovia Therapeutics appoints John Smither to board - Investing.com UK
Attovia Appoints New Independent Director - Intellectia AI
How MBX Biosciences’ New CEO-Chairman Structure Could Reframe the MBX Investment Narrative - Sahm
Goelzer Investment Management, Inc.'s MBX Biosciences Inc(MBX) Holding History - GuruFocus
FMR LLC's Strategic Acquisition of MBX Biosciences Inc Shares - GuruFocus
MBX Biosciences Announces CEO Transition and Leadership Updates - The Globe and Mail
Carmel-based MBX Biosciences makes leadership changes - Inside INdiana Business
MBX Biosciences (NASDAQ:MBX) Shares Gap DownShould You Sell? - MarketBeat
Stocks to Watch: Lulu's Fashion Lounge Holdings, MBX Biosciences, Rithm Property Trust - Moomoo
MBX Biosciences Appoints New CEO and CFO: Leadership Changes Announced in July 2026 8-K Filing - Minichart
MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth - TradingView
MBX Biosciences names Steve Hoerter as CEO, Kent Hawryluk steps down - Investing.com UK
MBX Biosciences appoints Steve Hoerter as CEO and John Smither as CFO - MSN
MBX Biosciences Appoints Steve Hoerter as CEO; Kent Hawryluk Steps Down - Moomoo
MBX Biosciences (Nasdaq: MBX) names new CEO and CFO, sets pay and equity - Stock Titan
MBX Biosciences Sinks as Sudden CEO Shake-Up Alarms Wall Street - TipRanks
MBX Biosciences stock falls on CEO and CFO leadership changes By Investing.com - Investing.com Nigeria
MBX Biosciences stock falls on CEO and CFO leadership changes - Investing.com India
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth - The Manila Times
MBX Biosciences, Inc. Announces the Appointment of John Smither as Chief Financial Officer, Effective July 13, 2026 - marketscreener.com
Enterprise value to EBIT forward of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
Candriam S.C.A. Purchases New Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
Price to sales forward of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
MBX Biosciences (NASDAQ:MBX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
MBX Biosciences (NASDAQ:MBX) Trading Down 6.9%Time to Sell? - MarketBeat
MBX Biosciences: From $10 To $64 As Hypoparathyroidism Drug Advances - RTTNews
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):